Legend Biotech Corporation
LEGNNASDAQHealthcare● Active
$31.27
$-1.35(-4.15%)
Market Cap$5.8B
P/E Ratio—
52W High$45.297
52W Low$16.24
Legend Biotech Corporation (LEGN) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · LEGN · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.03B | $0.63B | $0.29B | $0.12B | $0.07B |
| Cost of Revenue | $0.41B | $0.23B | $0.14B | $0.07B | $0.00B |
| Gross Profit | $0.62B | $0.39B | $0.14B | $0.05B | $0.07B |
| Gross Margin %(computed) | 60.34% | 62.60% | 49.42% | 44.14% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $0.41B | $0.41B | $0.38B | $0.34B | $0.31B |
| G&A Expenses | $0.14B | $0.14B | $0.11B | $0.08B | $0.05B |
| Total Operating Expenses | $0.76B | $0.70B | $0.58B | $0.51B | $0.46B |
| Operating Income | ($0.14B) | ($0.30B) | ($0.44B) | ($0.46B) | ($0.39B) |
| Operating Margin %(computed) | -13.27% | -48.35% | -154.13% | -389.40% | -569.97% |
| Interest Income | $0.04B | $0.06B | $0.05B | $0.01B | $0.00B |
| Interest Expense | $0.02B | $0.02B | $0.02B | $0.01B | $0.00B |
| Income Before Tax | ($0.28B) | ($0.16B) | ($0.52B) | ($0.45B) | ($0.41B) |
| Income Tax Expense | $0.01B | $0.02B | ($0.00B) | $0.00B | ($0.00B) |
| Net Income | ($0.30B) | ($0.18B) | ($0.52B) | ($0.45B) | ($0.40B) |
| Net Margin %(computed) | -28.85% | -28.22% | -181.75% | -381.48% | -586.38% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.60 | $-0.97 | $-2.94 | $-2.81 | $-2.74 |
| Wtd Avg Shares | 0.18B | 0.18B | 0.18B | 0.16B | 0.14B |
| EBITDA | ($0.23B) | ($0.11B) | ($0.48B) | ($0.42B) | ($0.39B) |
| EBITDA Margin %(computed) | -22.58% | -18.04% | -167.59% | -356.00% | -570.10% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Legend Biotech Corporation data
About Legend Biotech Corporation (LEGN) Income Statement
Legend Biotech Corporation (LEGN) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, LEGN reported revenue of $1.03B, gross profit of $0.62B (gross margin 60.34%), and net income of ($0.30B) — a net profit margin of -28.85%.
Frequently asked questions
LEGN · 4 questionsLegend Biotech Corporation (LEGN) reported revenue of $1.03B for 2025, up 64.0% year-over-year.
LEGN revenueLEGN salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08